Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21925853 | 0.73 | — | — | |
| SCHEMBL18416502 | 0.70 | — | — | |
| SCHEMBL23641712 | 0.70 | ADORA2A (0.35) | MEN1ALDH1A1KMT2AADORA2AADORA1 | |
| SCHEMBL21924820 | 0.67 | — | — | |
| SCHEMBL22650902 | 0.66 | SIGMAR1 (0.34) | MEN1ALDH1A1KMT2A | |
| SCHEMBL15357766 | 0.64 | MAPK13 (0.33) | MEN1ALDH1A1KMT2AADORA2AADORA1 | |
| SCHEMBL21347418 | 0.64 | MEN1 (0.31) | MEN1ALDH1A1KMT2A | |
| SCHEMBL19660823 | 0.63 | MEN1 (0.30) | MEN1ALDH1A1KMT2A | |
| SCHEMBL21137434 | 0.63 | ADORA2A (0.32) | MEN1ALDH1A1KMT2AADORA2AADORA1 | |
| SCHEMBL7078751 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11161864-B2 | Sting agonists | Venenum Biodesign, LLC (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | AJ SCIENCES (YIXING) CO., LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | Bicyclerd Limited (GB) | 2020-09-17 | — | — | US | disclosed |
| US-20200131209-A1 | NOVEL STING AGONISTS | Venenum Biodesign, LLC | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291096-A1 | BICYCLIC PEPTIDE LIGAND STING CONJUGATES AND USES THEREOF | STING1, BID, VIP | MEN1 1257/4885ALDH1A1 4871/4885KMT2A 3919/4885 |
| US-20200131209-A1 | NOVEL STING AGONISTS | STING1, CGAS, TBK1 | MEN1 1929/4885ALDH1A1 4836/4885KMT2A 3656/4885 |
| US-11161864-B2 | Sting agonists | STING1, IRF3, CGAS | MEN1 1416/4885ALDH1A1 4840/4885KMT2A 3694/4885 |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | STING1, IRF3, CGAS | MEN1 4490/4885ALDH1A1 3483/4885KMT2A 1936/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | MEN1 4490/4885ALDH1A1 3483/4885KMT2A 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.